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Atenolol has a low oral bioavailability and a short elimination half-life. 
Therefore, alternative route and delivery system is important. Transdermal 
iontophoresis, i.e. a systemic drug delivery via the skin, implementing a low 
intensity of electrical current, is one attractive candidate. This study evaluated 
feasibility of atenolol transdermal transport when iontophoresis is applied after 
enhancer pretreatment. There were 4 formulas prepared; 2 implemented 
iontophoresis for 3 hours (current density: 0.25 mA/cm2) while the others did 
not use iontophoresis. The enhancer was oleic acid (5 or 10% as a mixture in 
propylene glycol) with duration of pretreatment of one hour. Transport was 
evaluated in the diffusion studies across the fresh rat skin in a static-vertical 
diffusion system. Data were analyzed based on the numeric convolution method 
to obtain simulated Cp profiles as well as AUC of Cp profiles. Based on the 
simulated Cp, the best transport was achieved in Formula 3, where iontophoresis 
is performed across the skin, pretreated with 5% oleic acid for one hour. The 
value of simulated Cp indicated achievement of therapeutics level of atenolol, 
suggesting the feasibility of the atenolol delivery by iontophoresis. 




Bioavailabilitas oral yang rendah serta waktu paruh eliminasi yang pendek 
mendorong pentingnya sistem penghantaran alternatif atenolol. Transdermal 
iontoforesis, penghantaran obat sistemik melalui kulit menggunakan arus listrik 
intensitas rendah, merupakan kandidat atraktif. Penelitian ini mengevaluasi 
prospek penghantaran atenolol melalui kombinasi iontoforesis dengan 
praperlakuan enhancer. Empat formula atenolol dibuat; dua menggunakan 
iontoforesis (arus listrik 0,25 mA/cm2, selama 3 jam) dan dua tanpa 
iontoforesis. Enhancer yang digunakan adalah asam oleat (konsentrasi 5 atau 
10% dalam propilen glikol) dengan durasi praperlakuan selama 1 Jam. Transpor 
dievaluasi dengan studi difusi melewati kulit tikus segar pada sel difusi tipe 
vertikal. Data dianalisis menggunakan metode numeric convolution untuk 
mendapatkan profil simulasi kadar atenolol dalam plasma (Cp) dan area di 
bawah kurva (AUC) profil simulasi Cp tersebut. Berdasarkan profil Cp simulasi, 
transpor terbaik diperoleh pada Formula 3 dimana iontoforesis dilakukan 
melewati kulit yang diberi praperlakuan 5% asam oleat selama 1 Jam. Nilai Cp 
simulasi mengindikasikan tercapainya konsentrasi terapi atenolol. Hal ini 
menandakan prospek cerah penghantaran atenolol dengan iontoforesis. 
Kata kunci : atenolol, transdermal, iontoforesis, enhancer. 
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Introduction 
Atenolol is a selective adrenergic β-1 
blocker compound that widely used to treat 
several cardiovascular malfunctions including 
hypertension, angina pectoris, tachi-arrhythmic 
and myocardial infarct. Although has been 
available in a per-oral dosage form (tablet), 
atenolol has an intensive first pass metabolism 
resulting in a relatively low bioavailability 
(approximately 40%). In addition the 
compound is also relatively fast eliminated from 
the body, with a half  life of  6 hours (Mason, et 
al., 1979). Alternative route and delivery system 
is therefore of  great interest. One of  good 
candidate is transdermal iontophoresis, i.e. a 
systemic drug delivery across the skin, 
implementing application of  a low intensity of  
electrical current to drive drug molecules 
transport (Nugroho, 2005).  
Several studies have been conducted on 
transdermal iontophoretics delivery of  atenolol. 
In a recent study, Anroop and coworkers 
combined iontophoretics method with pro-
drug technique to obtain the best transport at a 
rate of  transport of  atenolol which could reach 
the therapeutic level (Anroop, et al., 2009). 
Another study evaluated the comparison of  
atenolol transdermal transport in a matrix 
formulation using oleic acid and iontophoresis. 
Although the in vivo studies indicated 
iontophoresis provided lower plasma and skin 
concentration than the influence of  oleic acid 
pretreatment alone, it was indicated as a good 
alternative for enhancing the transdermal 
transport of  atenolol (Inal, et al., 2008). 
Moreover, another research also combined 
iontophoresis and chemical enhancer as co-
treatment to facilitate atenolol transdermal 
transport. Such combination was reported to 
be promising, and based on the achieved in 
vitro atenolol flux, a therapeutically effective 
concentration could also be attained (Nair, et 
al., 2009). 
In this recent work, we studied feasibility 
of  combination of  iontophoresis and skin 
enhancer pre-treatment, i.e. using oleic acid in 
propylene glycol, to facilitate transdermal 
transport of  atenolol. The combination has 
been reported elsewhere to increase 
transdermal transport of  many drugs 
(Larrucea, et al., 2001; Murakami, et al., 1998). 
Evaluation was based on the simulated plasma 
concentration profiles of  atenolol, estimated 
using numeric convolution of  the transported 





Atenolol (HCl salt, purity of  99.5%, Calao, 
Milano Italy) was obtained as a gift from PT Kalbe 
Farma Jakarta Indonesia. Propylene glycol, oleic 
acid, mannitol, di-sodium hydrogen phosphate 
(Na2HPO4), Sodium di-hydrogen phosphate 
(NaH2PO4) and sodium chloride (analytical grade, 
Merck, Darmstadt, Germany) were purchased from 
PT General Labora Yogyakarta Indonesia. The 
diffusion studies were performed in a static-vertical 
diffusion cell (prepared by Department of  Physical 
Engineering Institut Teknologi Bandung, Bandung, 
Indonesia (see Figure 1).  
 
Methods 
Rat skin Preparation 
Fresh rat skin was obtained directly after 
sacrificing animals using a lethal dose of  ether 
inhalation. Skin was carefully cleaned from its hair 
by electric clipping without any damage, wound or 
scratch on the skin surface. Skin fat was removed by 
using scalpel. Thereafter, skin was cleaned with aqua 
pro injection (API) prior to cutting into circular 
shapes (using a special punch) with a diameter of  2 
cm. Skin was then placed onto the diffusion cell, 
either for a pretreatment studies or directly for a 
transport study. 
 
Rat Skin pretreatment 
After being mounted into diffusion cell, skin 
was exposed to the enhancer solution; which filled 
into the donor compartment of  the cell. The 
enhancer consists of  oleic acid in propylene glycol 
based on scheme provided in Table I. Pretreatment 
was performed for one hour. After the 
pretreatment, the enhancer mixture was removed 
from the cell and skin was then cleaned by soaking 
and spraying with API 5 times. Thereafter skin was 
ready for an iontophoretic study. 
 
Transport study 
After a proper mounting of  skin, the cell was 
then secured by joining and screwing the donor and 
the acceptor parts together. The donor phase of  the 
system was then filled in with 1 mg/ml atenolol 
solution (in 5mM citric buffer at pH of  5, 
containing 4g/l NaCl). The acceptor phase was 
filled with 0.15M phosphate buffer saline at pH 7.4. 
Mannitol was added (6 g in 250ml buffer) in the 
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donor solution to balance the tonicity of  donor and 
acceptor media. The iontophoretics study was 
performed for 3 hours using the iontophoretics 
power supply (prepared by Department of  
Electronics, Leiden/Amsterdam Center for Drug 
Research, Leiden The Netherlands) connected to 
appropriate electrodes, i.e anode (made of  silver 
plate) and cathode (made of  Silver/Silver chloride), 
dipped in the donor and acceptor medium. Both 
silver and silver chloride were purchased from 
Merck, Darmstadt Germany, with a purity of  99.9%. 
Iontophoretic transport study was performed for 3 
hours, during which, samples were collected 
periodically from the opening column on the 
acceptor phase side (see Figure 1). 
 
HPLC analyses 
Samples were analyses using an HPLC 
method (HPLC Prominence Shimadzu, Kyoto, 
Japan) using a LichroCART 250-4 RP 18 (5um) 
(Merck, Darmstadt Germany) at a flow rate of  
0.7ml/minute. The eluent consists of  a mixture of  
0.05M pH 3.2 acetic buffer and acetonitrile at 70:30 
ratio. Atenolol was eluted with at a retention time of  
4.6 minute and identified using UV absorption 
detector (SPD 20A Shimadzu, Kyoto, Japan) at a 
wavelength of  270nm. 
 
Preparation of atenolol solution 
Four formulas of  atenolol solution were 
prepared. Details composition of  those, are 
presented in table I. The studied factors in this 
research were iontophoretics current (0.25 mA/cm2 
and 0 mA/cm2 (without current)) and 




Transport profiles obtained during the 
studies were analyzed using a numeric convolution 
method as proposed previously (Qi, et al., 2003; 
Welin-Berger, et al., 2003), to obtain the predicted 
plasma concentration profiles, assuming a 1 by 1 in 
vitro – in vivo correlation. Parameters of  disposition 
of  atenolol were obtained from a previously 
published report (Wan, et al., 1979) Convolution was 
performed using Kinetica (version 5.0, Thermo 
Science, USA) implementing the default template 
provided in this software. Profiles of  simulated Cp 
versus time were then further analyzed to obtain 
 
 
Figure 1. Scheme of static vertical-diffusion cells showing: donor compartment (1), diffusion 
membrane (rat skin) (2), acceptor compartment (3), magnetic bar (4), sampling port (5), 
anode (6) and cathode (7). 
 
Tabel I. Formulation design of transdermal iontophoretic transport of atenolol  
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estimates of  area under the curve during 3 hours of  
transport (AUC). This parameter was used to 
evaluate the  effectiveness  of   transport  on  those 4  
formulas. Statistical analyses were performed based 
on ANOVA test followed by a Tukey test (p<0.05). 
 
Results and Discussion  
Data of  atenolol transport under those 4 
conditions are presented in Figure 2. There was 
a relatively similar level of  atenolol transport in 
formula 1, 2 and 4. Levels of  transport in 
formula 3, i.e. iontophoresis at a current level 
of  0.25mA/cm2 across skin pretreated with a 
low concentration of  oleic acid (5%), was 
higher than others (p<0.05).  
A better insight into the transport level 
of  atenolol in this study was obtained by the 
results of  the numeric convolution method 
simulating atenolol plasma concentration. 
Typical examples are presented in Figure 3 
where the simulated atenolol concentrations in 
plasma of  Formula 1 and 3 are depicted. 
Similar to the levels of  atenolol transport, Cp 
levels in Formula 3 was also the highest 
(p<0.05).  
Moreover, the estimated area under the 
curve during 3 hours of  the transport (AUC) 
presented in Figure 4 also show brighter view 
regarding correlation of  the atenolol transport 
on those 4 formulas. The AUC in Formula 3 
was the highest than others (p<0.05). This is in 
contrast to the parameter values in Formula 1, 
2 and 4 which were similar one to each other. 
Such condition is again in agreement with that 
indicated by the level of  atenolol transport. 
Concerning AUC as one measure of  
bioavailability, it might suggest that 
combination of  iontophoresis and oleic acid 
skin pretreatment at a concentration of  5% 
provided the best transport of  atenolol.  
Our finding in this study is basically in 
agreement to what have often been reported 
that skin pretreatment especially with oleic acid 
resulted in a significant impairment of  the skin 
barrier integrity. Similarly, Nair and coworkers 
reported that combination of  oleic acid and 
iontophoresis as co-treatment enhanced 
atenolol transport significantly. In their study, a 
range of  oleic acid concentration of  1 - 5% 
w/v was used in a co-treatment method (Nair, 
et al., 2009). There was a difference in the 
method of  enhancer application, however, as in 




Figure 2. Profiles of atenolol transport in 4 formulas of transdermal transport of atenolol during 3 
hours of diffusion studies in vitro in a static vertical diffusion cells across the fresh rat 
skin. Data are presented as mean + SD (n=3-4). 
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It is interesting that further increase in 
concentration of  oleic acid used for skin 
pretreatment did not further influence the level 
of  transport of  atenolol, either in situation with 
or without iontophoresis. This is beyond the 
general expectation that oleic acid could act as 
enhancer to perturb the integrity of  skin barrier 
(Jiang, et al., 2000; Yu, et al., 2003). In such 
manner, the higher concentration of  oleic acid 
pretreatment should result in a more permeable 
skin, thus the higher the transport.  
The reasons behind these facts were not 
fully understood. However, considering its 
nature as lipid substance, it can be deduced that 
the presence of  oleic acid on the surface of  
skin after pretreatment could possess problem 
for the atenolol molecule to pass through the 
skin. As the study was performed at a pH of  5, 
due to the pKa of  atenolol at around 9.6 
(Vogelpoel, et al., 2004), almost 100% of  
atenolol was present as an ionic state. In such 
case, the ionic atenolol will have difficulties to 
 
 
Figure 3. Profiles of simulated atenolol plasma (Cp) based on numeric convolution method of the 





Figure 4. Histogram of AUC of simulated Cp profile during the transdermal transport of atenolol. 
Data are presented as mean + SD (n=4). 
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cross the skin with some amount of  lipid traces 
might still be present on skin surface. In 
addition, the presence of  lipid could also 
reduce the role of  skin as a perm-selective 
membrane which allows drug transport driven 
by electroosmotic and electrorepulsive force 
during iontophoresis (Luzardo-Alvarez, et al., 
1998). Such hindrance should be more 
prominent at higher lipid concentration. This 
explained the reduced iontophoretic atenolol 
transport at higher oleic acid concentration.  
Finally, it is important to evaluate 
whether therapeutics level could be 
achieved based on the results of  the in 
vitro studies. The simulated Cp profiles 
indicated that a maximum value of  
0.8ng/mL could be achieved in Formula 3 
(with an atenolol donor concentration of  1 
mg/mL). This was calculated based on the 
area of  diffusion of  the system at a value 
of  1.88cm2. In case that a patch at a size of  
20cm2 is prepared, the theoretical 
concentration of  atenolol could be 
estimated in Equation (1). 
Cp = 0.8 ng/mL * (20 cm2/1.88 cm2) = 8.5 
ng/mL…………..(1) 
Considering the solubility of  atenolol 
in water at a value of  26.5 mg/mL 
(Anonymous, 2009) and assuming that 
transdermal transport is linearly increased 
with concentration in donor phase as          
often reported with several drugs (Nugroho, 
et al., 2004; Nugroho, et al., 2005), if  a 
concentration of  25mg/ml is used, then the 
concentration of  atenolol in plasma could 
be estimated in Equation (2). 
Cp = 8.5 ng/mL * (25 mg/mL/ 1 mg/mL) 
= 213 ng/mL=0.213 µg/mL…..(2) 
According to Puglia dan Bonina, 
therapeutic window of  atenolol is in a range 
between 0.2 until 0.6 µg/mL (Puglia and 
Bonina, 2008). Therefore, based on the 
aforementioned calculation, iontophoresis in 
combination with oleic acid pretreatment could 
achieve this important level. This indicated the 
feasibility of  transdermal iontophoretic 
transport of  atenolol to be further developed.  
 
Conclusion 
When atenolol is delivered using 
iontophoresis after a pretreatment of  oleic acid 
at a concentration of  5% (in propylene glycol) 
with duration of  1 hour, a therapeutics level of  
the beta-blocker could be achieved, indicating 
the bright prospect of  the formulation to be 
developed in future. 
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